Analyst & Investor Briefing

RNS Number : 0694Q

Hutchison China Meditech Limited

09 October 2013

 



Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)

Chi-Med's Pharmaceutical R&D Business - Analyst & Investor Briefing

London: Wednesday, 9 October 2013: Chi-Med today announces that further to the announcement made on 3 October 2013 relating to the briefing for investors and analysts to be held at The Brewery (The James Watt room), 52 Chiswell Street, London, EC1Y 4SD today at 9:30 am, it wishes to state that no new material information will be disseminated at the briefing.

Ends

Enquiries

Chi-Med    Christian Hogg, CEO	Telephone:      [phone]
Panmure Gordon (UK) Limited    Richard Gray    Andrew Potts    Grishma Patel	Telephone:      [phone]
Citigate Dewe Rogerson    Anthony Carlisle    David Dible	Telephone:      [phone] Mobile:             [phone] Mobile:             [phone]

Notes to Editors

About HMP

HMP is a novel drug R&D division focusing on discovering, developing and commercialising innovative therapeutics in oncology and autoimmune diseases.  With a team of around 200 scientists and staff, its pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and Greater China.

HMP is majority owned by Chi-Med.  For more information, please visit: www.hmplglobal.com.

About Chi-Med

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.  For more information, please visit: www.chi-med.com.

 

END

 

 

MSCFMMGGKLRGFZG